Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimetidine for prevention of cisplatin-induced nephrotoxicity in head and neck cancer
NL-OMON21483Active, not recruiting
- Sponsor
- Erasmus MC Cancer Institute
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cimetidine and cisplatin in head and neck cancer (HNC) (2 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Renal biomarker assessment. Started May 2010; status: active, not recruiting.
02
Drugs
cimetidinecisplatin
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NL-OMON21483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21483.